Department of Internal Medicine, Faculty of Medicine, İstanbul University-Cerrahpasa, İstanbul, Turkey
Department of Internal Medicine, Taksim Training and Research Hospital, İstanbul, Turkey
Turk J Med Sci. 2020 Dec 28;51(2):735-742. doi: 10.3906/sag-2008-37.
BACKGROUND/AIM: To evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM).
Ninety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit.
Physical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores, and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight, and body mass index were significantly higher in Group A.
The QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.
背景/目的：评估钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂治疗对 2 型糖尿病（T2DM）患者生活质量（QoL）、睡眠质量（SQ）和焦虑水平的影响。
纳入了 97 名在三级护理医院糖尿病诊所就诊的 2 型糖尿病患者。50 名患者被随机分配接受 SGLT2 抑制剂联合基础治疗（A 组），47 名患者继续接受基础治疗或根据需要添加其他药物（B 组）。招募了 30 名健康对照者（C 组）。所有组均在基线和最终访视时接受了土耳其版 36 项简短健康调查量表（SF-36）、匹兹堡睡眠质量（PSQ）和贝克焦虑量表（BAI）评估。
A 组在随访期末，SF-36 的身体功能、情感角色限制、活力、心理健康、疼痛和总体健康感知评分显著改善。PSQ 和 BAI 评分以及低血糖在所有组中均无显著变化。A 组的 HbA1c 水平、体重和体重指数的干预相关变化明显更高。
接受 SGLT2 抑制剂治疗的糖尿病患者的生活质量得到了改善。这可能是由于参与者体重减轻所致。
